This work is licensed under a Creative Commons Attribution 4.0 International License.
Lavracin [D2G,P3K,Y4F,A17G,V18E,R19I]
General Information
DRACP ID DRACP00774
Peptide Name Lavracin [D2G,P3K,Y4F,A17G,V18E,R19I]
Sequence WGKFFAGVKKLTKAILGEIA
Sequence Length 20
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| MEC-7 | Invasive breast carcinoma of no special type | Carcinoma | EC50=25µM | MTT assay | 72h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HDME: Not active up to 100 µM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antibacterial
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C106H169N25O24
Absent amino acids CDHMNPQRSY
Common amino acids K
Mass 251676
Pl 10.8
Basic residues 4
Acidic residues 1
Hydrophobic residues 11
Net charge 3
Boman Index 868
Hydrophobicity 49.5
Aliphatic Index 107.5
Half Life
Mammalian: 2.8 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 5500
Absorbance 280nm 289.47
Polar residues 4
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 28799716
Title Rational Design of Membrane-Pore-Forming Peptides.
Year 2021
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.